

This PANNA newsletter will also be available at the website: [www.pannastudy.com](http://www.pannastudy.com)

A newsletter will be issued once per 4 months to update you on the status of the study and inclusions.

### Centres

All centres in *The Netherlands; UK; Italy; Germany; Belgium; Ireland* are open for inclusion.

*Canada*: ethics approval.

*Spain*: an additional centre (Granada) will participate.

*France*: working on submission.


### List of compounds under investigation

**panna**

Etravirine, Intence, ETV  
 Emtricitabine, Emtriva or FTC  
 Tenofovir, Viread, TDF  
 Atazanavir, Reyataz, ATV  
 Fosamprenavir, Telzir, FPV  
 Darunavir, Prezista, DRV  
 Tipranavir, Aptivus, TPV  
 Indinavir, Crixivan, IDV  
 Raltegravir, Isentress, RAL  
 Enfuvirtide, Fuzeon, T-20  
 Maraviroc, Celsentri, MVC  
 Efavirenz, Stocrin, EFV\*  
 \*UK/Ireland only

### Inclusions

38 subjects signed informed consent.



### Emtricitabine / tenofovir arms closed now!


Patients on tenofovir / emtricitabine as the only compounds of the PANNA list cannot be included anymore.

### First results presented

#### 12th International Workshop on Clinical Pharmacology of HIV Therapy

We presented the first raltegravir data collected in the PANNA study in Miami. See results below.

#### Individual AUCt values



#### Cord blood/maternal plasma ratios

	conc maternal at delivery (mg/L)	conc. cord blood (mg/L)	cord blood / maternal plasma ratio
GB0201	0.615	0.628	1.02
IT0103	0.063	0.073	1.16

### Conclusion

In this small population (n=6) exposure to raltegravir was not lower during pregnancy (third trimester) than post-partum. This is in contrast to a number of other antiretroviral agents, especially protease inhibitors.

Raltegravir efficiently crosses the placenta.

These results need to be confirmed in a larger group of patients.

Thanks to the investigator contributing to these data (see the poster enclosed).

### Have a nice holiday season!

**I will be on holiday from June 17 – July 18.** In my absence you can contact David Burger in case of questions. E-mail [d.burger@akf.umcn.nl](mailto:d.burger@akf.umcn.nl). Telephone number as below.

Angela Colbers  
 Project manager  
 E-mail: [A.Colbers@akf.umcn.nl](mailto:A.Colbers@akf.umcn.nl)  
[HIVPharmacology@akf.umcn.nl](mailto:HIVPharmacology@akf.umcn.nl)  
 Radboud University Nijmegen Medical Centre, Internal postal code 864,  
 Department of Pharmacy,  
 P.O. Box 9101, 6500 HB Nijmegen  
 Phone: + 31 (0)24 - 361 64 05  
 Fax: + 31 (0)24- 366 87 55